Leave Your Message
ADT1357-Lexatumumab Biosimilar-Anti-TNFRSF10B/CD262 mAb-Research Grade
Antibody

ADT1357-Lexatumumab Biosimilar-Anti-TNFRSF10B/CD262 mAb-Research Grade

  • Catalog Number ADT1357
  • Host CHO Cells
  • Species Human
  • Target TNFRSF10B/CD262
  • Application ELISA, IP, FC, Functional assay, Neut, IF

By maintaining stringent quality control throughout the production process, we provide blocking antibody that meet the highest standards of purity and performance, making them ideal for research applications.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

TNFRSF10B is a type I transmembrane protein with an extracellular domain containing cysteine-rich motifs for ligand binding, a transmembrane domain, and a cytoplasmic death domain essential for apoptosis signaling. Unlike some decoy receptors in the same family (e.g., DcR1/DcR2), TNFRSF10B lacks a truncated death domain, enabling it to fully transmit pro-apoptotic signals.

Product Specification

Catalog Number

ADT1357

Product Name

ADT1357-Lexatumumab Biosimilar-Anti-TNFRSF10B/CD262 mAb-Research Grade

Clonity

Monoclonal

Alternate Names

TNFRSF10B antibody,  CD262 antibody,  cd262 mouse,  anti-mouse CD262 antibody,  anti-CD262 antibody,  anti CD262 antibody,  recombinant CD262,  anti-CD262 monoclonal antibody,  CD262 antibodies,  CD262 recombinant antibody,  CD262 blocking antibody,  TNFRSF10B recombinant antibody,  TNFRSF10B blocking antibody

Alias

HGS-ETR2

Host

CHO Cells

Species

Human

Target

TNFRSF10B/CD262

Gene ID

8795

Isotype

IgG1 Lambda

Size

1mg, 5mg

Research Area

Cancer

CAS Number

845816-02-6

Product Description

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5,  APO-2),  intended for the treatment of cancer. HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology. Development was discontinued in 2015.

Mechanism of Action

Lexatumumab agonizes the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2),  triggering the extrinsic apoptotic pathway.

Metabolism

Lexatumumab has a long half-life and is distributed throughout the bloodstream and tissues.

Application

ELISA,  IP,  FC,  Functional assay,  Neut,  IF

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reactivity

Human

Reference

1. Mora-Molina R,  et al. Int J Mol Sci,  2022 Aug 12. PMID 36012252
2. Qin J,  et al. Expert Rev Respir Med,  2022 Jul. PMID 35822538
3. Sullivan GP,  et al. Dev Cell,  2020 Mar 23. PMID 32109381